Table of Contents
EXECUTIVE SUMMARY
- Figure1: Growth in biomarker market 2007-2015
- What are biomarkers?
- Why are they important?
- Figure 2: Potential impact of biomarkers on disease pathways
- What technologies are involved?
- What impact will biomarkers have on R&D?
- Figure 3: Potential impact of biomarkers on R&D
- Who are the major biomarker players and in what research area?
- Cancer biomarker companies
- Cardiovascular biomarker companies
- CNS biomarkers companies
- Company Analysis Criteria
- Biomarker technology & platforms
- Association/clinical studies
- Management strategy
- Application & potential
CANCER MARKET & REVENUES
- Market revenues - global
- Figure 1: Global cancer drugs sales (2007)
- Market revenues - leading brands
- Figure 2: Leading cancer brands (2007)
- Market revenues - leading players
- Figure 3: Top 10 oncology players (2007 revenues)
- CANCER EPIDEMIOLOGY, DIAGNOSIS, SCREENING & TREATMENT
- Epidemiology
- Table 1: Cancer Statistics for four most common cancers, 2008
- Diagnosis
- Screening
- Table 2: Cancer screening
- Current & future treatment
- Future treatment
- Figure 4: Anticancer drugs in clinical development
- CANCER BIOMARKERS
- Cancer biomarker R&D
- Table 3: Types of biomarker
- Known cancer biomarkers
- Table 4: Commercially available known cancer biomarker diagnostics
- Probable and possible valid cancer biomarkers
- Table 5: Probable cancer biomarkers diagnostics
- Table 6: Possible cancer biomarkers diagnostics
- CANCER BIOMARKER OPPORTUNITIES & CHALLENGES
- BIOMARKER MARKET
- Biomarker market revenues - global
- Figure 8: Global biomarker sales in 2007
- Cancer biomarker market revenues - global
- Figure 9: Global cancer biomarker sales in 2007
- Future biomarker market revenues - global
- Figure 10: Global biomarker sales in 2015
- Future cancer biomarker market revenues - global
- Figure 11: Global cancer biomarker sales in 2015
- CANCER BIOMARKER TRENDS
- Table 7: Recent deals in oncology biomarkers
- Pharma and specialty pharma deals
- Collaborations with service providers
- Collaborations with academics and consortia
- BIOMARKER ANALYSIS
- DNA biomarkers
- RNA and microRNA biomarkers
- Proteomic biomarkers
- KEY BIOMARKER COMPANIES ANALYSED
- KEY BIOMARKER EVALUATION CRITERIA
CANCER BIOMARKER- COMPANY ANALYSIS
- Abbott Diagnostics
- Biomarker novelty & technology platform
- Figure 12: Abbott' s UroVysion bladder cancer test
- Association studies/clinical data
- Pivotal Trial
- Table 7: Comparison of UroVysion vs Cystoscopy/Histology for Detection
of Bladder Cancer Recurrence by Stage and Grade*
- Management strategy
- Application & market potential
- Biomarker analysis
- Affymetrix
- Biomarker novelty & technology platform
- Figure 13: Affymetrix' approach to biomarker discovery, validation and
clinical utility applications
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- Agendia BV
- Biomarker novelty & technology platform
- Association studies/clinical data
- Figure 14: MammaPrint Profile vs NIH Consensus Criteria
- Management strategy
- Application & market potential
- Biomarker analysis
- AltheaDx
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- AVEO Pharmaceuticals
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- AviaraDx
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- BG Medicine
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Figure 15: BG Medicines Biomarker Programme
- Application & market potential
- Biomarker analysis
- Beckman Coulter
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- BioCurex
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- Biomedical Diagnostics
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- Biomerica
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- Bruker Daltonics
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- Caprion Proteomics
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- Clinical Data
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- Celera
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- Dako Denmark A/S
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- DxS Ltd
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- Epigenomics AG
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- Epistem Plc
- Biomarker novelty & technology platform
- Figure 16: Epistem' s Biomarker Drug Development Programme
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- GeneNews
- Biomarker novelty & technology platform
- Figure 17: GeneNews' Sentinel Principle
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- Fujirebio Diagnostics, Inc
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- Genomic Health
- Biomarker novelty & technology platform
- Figure 18: Oncotype Dx test for invasive breast cancer
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- Gen-Probe
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- Genzyme Genetics
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- InterGenetics
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- Ipsogen Therapeutics
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Figure 19: Oncotype Dx test for invasive breast cancer
- Application & market potential
- Biomarker analysis
- Laboratory Corporation of America
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- Matritech
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- Monogram Biosciences
- Biomarker novelty & technology platform
- Association studies/clinical data
- Figure 21: VeraTag Clinical Data: Bordet Cohort
- Management strategy
- Application & market potential
- Biomarker analysis
- Orion Genomics
- Biomarker novelty & technology platform
- Figure 22: Orion' s MethylScope
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- Oxford Genome Biosciences (UK) Ltd
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- Power3 Medical Products
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Figure 23: Powder3' s business strategy
- Application & market potential
- Biomarker analysis
- Predictive Biosciences
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- Provista Life Sciences
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- Quest Diagnostics
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- Roche Diagnostics
- Biomarker novelty & technology platform
- Figure 24: Diagnostic marker candidate to a product
- Association studies/clinical data
- Figure 25: Biomarkers distinguish Leukaemia subclasses
- Management strategy
- Application & market potential
- Biomarker analysis
- SuperArray Bioscience Corporation
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- Third Wave Technologies
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- Upstream Biosciences
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- Veridex, LLC
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- Vermillion
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
CAncer biomarker APPENDIX 1
- Table 8: Global biomarker sales 2007-20015E
CAncer biomarker APPENDIX 2
- Table 8: Global cancer biomarker sales 2007-20015E
CAncer biomarker APPENDIX 3
- Company Analysis Criteria
- Biomarker technology & platforms
- Association studies
- Management strategy
- Application & potential
- Table 9: Key cancer biomarker companies
- Figure 26: Leading Cancer Biomarker Companies - Service providers,
Technology Providers, Biomarker Discovery & Diagnostic Developers
GLOSSARY
ACRONYMS
BIBLIOGRAPHY & end NOTES
CNS MARKET & REVENUES
- Market revenues - global
- Figure 1: Global CNS drugs sales (2007)
- Market revenues - leading brands
- Figure 2: Leading CNS brands (2007)
- Market revenues - leading players
- Figure 3: Top 10 CNS players (2007 revenues)
- CNS EPIDEMIOLOGY, DIAGNOSIS, SCREENING & TREATMENT
- Epidemiology
- Table 1: CNS statistics for the most common CNS disorders, 2008
- Diagnosis
- Table 2: Indication for CT and MRI in the CNS
- Screening
- Current & future treatment
- Table 3: Classes of CNS drugs approved for acute and chronic conditions
- Future treatment
- Figure 4: CNS drugs in clinical development
- CNS BIOMARKERS
- CNS biomarker R&D
- Figure 5: Imaging biomarkers as surrogate endpoints
- Table 4: Types of biomarker
- Known CNS biomarkers
- Table 5: Commercially available known CNS biomarker diagnostics
- Probable and possible valid CNS biomarkers
- Table 6: Probable CNS biomarkers diagnostics
- Table 7: Possible CNS biomarkers diagnostics
- CNS BIOMARKER OPPORTUNITIES & CHALLENGES
- Opportunities
- Figure 7: CNS biomarker opportunities
- Challenges
- Figure 8: CNS biomarker challenges
- BIOMARKER MARKET
- Biomarker market revenues - global
- Figure 9: Global biomarker sales in 2007
- CNS biomarker market revenues - global
- Figure 10: Global CNS biomarker sales in 2007
- Future biomarker market revenues - global
- Figure 11: Global biomarker sales in 2015
- Future CNS biomarker market revenues - global
- Figure 12: Global CNS biomarker sales in 2015
- CNS BIOMARKER TRENDS
- Table 8: Recent deals in the oncology biomarkers
- Pharma deals
- Collaborations with CNS discovery companies
- Collaborations with academics and consortia
- BIOMARKER ANALYSIS
- DNA biomarkers
- Proteomic biomarkers
- Metabolomic biomarkers
- Electrophysiology biomarkers
- Imaging biomarkers
- KEY BIOMARKER COMPANIES ANALYSED
- KEY BIOMARKER EVALUATION CRITERIA
CNS BIOMARKER- COMPANY ANALYSIS
- Affymetrix
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- Applied NeuroSolutions
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- Banyan Biomarkers
- Biomarker novelty & technology platform
- Figure 14: Source Of Banyans TNI biomarkers
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- BG Medicine
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- Biosite, Inc
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- Biospective
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- Celera, Inc
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- Clinical Data Inc
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- Curidium Medica
- Biomarker novelty & technology platform
- Association studies/clinical data
- Figure 17: Curidium' s PsychINDx test for schizophrenia/bipolar disorder
- Management strategy
- Application & market potential
- Digilab Peptidomics
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- EnVivo Pharmaceuticals
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- Innogenetics NV
- Biomarker novelty & technology platform
- Figure 18: Innogenetic multiparameter analysis
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- KineMed, Inc
- Biomarker novelty & technology platform
- Figure 19: KineMarker technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- Lipomics Technologies
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- Luminex Corporation
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Figure 20: Luminex is capturing end-user market share
- Application & market potential
- Biomarker analysis
- Memory Pharmaceuticals Corporation
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- Metabolon, Inc
- Biomarker novelty & technology platform
- Figure 21: Metabolon integrated analytic platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- Nanogen, Inc
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- Nanosphere, Inc
- Biomarker novelty & technology platform
- Figure 22. Nanosphere' s gold nanoparticle technology
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- Nymox Pharmaceutical
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- Competitor Ratio Analysis Score = 12/40
- Osta Biotechnologies
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- Phenomenome Discoveries, Inc
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- PPD, Inc
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- Competitor Ratio Analysis Score = 16/40
- Power3 Medical Products
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- Provista Life Sciences
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- Psynova Neurotech Ltd
- Biomarker novelty & technology platform
- Association studies/clinical data
- Figure 23: Two proteins identified in CSF are also biomarkers in serum
- Management strategy
- Application & market potential
- Biomarker analysis
- Satoris, Inc
- Biomarker novelty & technology platform
- Association studies/clinical data
- Figure 24: Early identification of Alzheimer' s disease in at-risk MCI
patients
- Management strategy
- Application & market potential
- Biomarker analysis
- Siemens Medical Solutions
- Biomarker novelty & technology platform
- Figure 25: Siemens Integrated in vivo & in vitro diagnostic suites
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- Competitor Ratio Analysis Score = 20/40
- SuperArray Bioscience Corporation
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
CNS biomarker APPENDIX 1
- Table 9: Global biomarker sales 2007-20015E
CNS biomarker APPENDIX 2
- Table 10: Global CNS biomarker sales 2007-20015E
CNS biomarker APPENDIX 3
- Company Analysis Criteria
- Biomarker technology & platforms
- Association studies
- Management strategy
- Application & potential
- Table 9: Key CNS Biomarker Companies
- Figure 26: Leading CNS Biomarker Companies - Service Providers,
Technology Providers, Biomarker Discovery & Diagnostic Developers
GLOSSARY
ACRONYMS
BIBLIOGRAPHY
CARDIOVASCULAR MARKET & REVENUES
- Market revenues - global
- Figure 1: Global cardiovascular disease drug sales 2007
- Market revenues - leading brands
- Figure 2: Leading Cardiovascular brands (2007)
- Market revenues - leading players
- Figure 3: Top 10 cardiovascular players (2007 revenues)
- CARDIOVASCULAR EPIDEMIOLOGY, DIAGNOSIS, SCREENING & TREATMENT
- Epidemiology
- Figure 4: Breakdown of deaths from cardiovascular diseases in the US
(2004)
- Diagnosis
- Screening
- Table 1: Screening for cardiovascular disease
- Current treatments
- Table 2: Cardiovascular therapeutic drug categories and their
indications
- Future treatments
- Figure 5: Drugs in clinical development for heart disease
- CARDIOVASCULAR BIOMARKERS
- Cardiovascular biomarker R&D
- Figure 6: Impact of biomarkers on the drug R&D process
- Table 3: Types of biomarker
- Known cardiovascular biomarkers
- Table 4: Commercially available cardiovascular diagnostics
- Probable and possible valid cardiovascular biomarkers
- Table 5: Probable cardiovascular biomarkers
- Table 6: Possible cardiovascular biomarkers
- CARDIOVASCULAR BIOMARKER OPPORTUNITIES & CHALLENGES
- Opportunities
- Figure 7: Cardiovascular biomarker opportunities
- Challenges
- Figure 8: Cardiovascular biomarker challenges
- BIOMARKER MARKET
- Biomarker market revenues - global
- Figure 9: Global biomarker sales in 2007
- Cardiovascular biomarker market revenues - global
- Figure 10: Global cardiovascular biomarker sales in 2007
- Future biomarker market revenues - global
- Figure 11: Global biomarker sales in 2015
- Future cardiovascular biomarker market revenues - global
- Figure 12: Global cardiovascular biomarker sales in 2015
- CARDIOVASCULAR BIOMARKER TRENDS
- Table 7: Recent deals in cardiovascular biomarkers
- Pharma and specialty pharma deals
- Collaborations with service providers
- Collaborations with academics and consortia
- BIOMARKER ANALYSIS
- Assays for circulating biomarkers
- DNA and RNA biomarkers
- Proteomic, metabolomic biomarkers
- Systems biology for biomarker discovery
- Imaging biomarkers
- KEY BIOMARKER COMPANIES ANALYSED
- KEY BIOMARKER EVALUATION CRITERIA
CARDIOVASCULAR BIOMARKERS - COMPANY ANALYSIS
- Abbott Diagnostics
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- Atherotech
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- Affymetrix
- Biomarker novelty & technology platform
- Figure 13: Affymetrix' approach to biomarker discovery, validation and
clinical utility applications
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- Beckman Coulter
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- Berkeley HeartLab
- Biomarker novelty & technology platform
- Figure 14: Markers of cardiovascular disease measured at Berkeley
HeartLab
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- BG Medicine
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Figure 15: BG Medicine' s Biomarker Programme
- Application & market potential
- Biomarker analysis
- CardioDx
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- Competitor Ratio Analysis Score = 9/40
- Celera
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- CIS Biotech
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- Clinical Data
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- Compugen
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- Critical Diagnostics
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- deCODE Genetics
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Figure 16: deCODE' s approach to target discovery and development
- Application & market potential
- Biomarker analysis
- diaDexus
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- Entelos
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- FoxHollow Technologies
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- GE Healthcare
- Biomarker novelty & technology platform
- Figure 17: Cardiology focus at GE Healthcare
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- Genomas
- Biomarker novelty & technology platform
- Figure 18: PhysioGenomics Technology from Genomas
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- Inverness Medical Innovations
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- Jurilab
- Biomarker novelty & technology platform
- Figure 19: Jurilab' s Genetic Discovery Method
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- Competitor Ratio Analysis Score = 12/40
- Laboratory Corporation of America
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- Lipomics Technologies
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- LipoScience
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- Competitor Ratio Analysis Score = 15/40
- Nanosphere Inc
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- Osmetech Molecular Diagnostics
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- Competitor Ratio Analysis Score = 12/40
- PrognostiX
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- Quest Diagnostics
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- Competitor Ratio Analysis Score = 27/40
- Roche Diagnostics
- Biomarker novelty & technology platform
- Figure 20: Roche' s technologies for biomarker discovery and development
- Association studies/clinical data
- Figure 21: Roche' s clinical trial programme for cardiac biomarker
NT-proBNP
- Management strategy
- Application & market potential
- Biomarker analysis
- Siemens Medical Solutions
- Biomarker novelty & technology platform
- Figure 22: Siemens Integrated in vivo & in vitro diagnostic suites
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- Singulex
- Biomarker novelty & technology platform
- Figure 23: Sensitivity of Singulex' s Erenna system compared to ELISA
and bead-based fluorescence readout systems
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- SuperArray Bioscience Corporation
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- Vermillion
- Biomarker novelty & technology platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
- Zora Biosciences OY
- Biomarker novelty & technology platform
- Table 8: Zora metabolite profiling platform
- Association studies/clinical data
- Management strategy
- Application & market potential
- Biomarker analysis
Cardiovascular biomarker APPENDIX 1
- Table 9: Global biomarker sales 2007-20015E
Cardiovascular biomarker APPENDIX 2
- Table 10: Global cardiovascular biomarker sales 2007-20015E
Cardiovascular biomarker APPENDIX 3
- Company Analysis Criteria
- Biomarker technology & platforms
- Association studies
- Management strategy
- Application & potential
- Table 9: Key cardiovascular biomarker companies
- Figure 26: Leading Cardiovascular Biomarker Companies - Service
providers, Technology Providers, Biomarker Discovery & Diagnostic
Developers
GLOSSARY
ACRONYMS
BIBLIOGRAPHY & end NOTES
|
Related Report
|
View Cart
